Launching the Burrill Israel Fund

Launching of the Burill Israel Fund

May 24, 2012 at 17:00

Jerusalem is one of the principal poles on R&D in Life Sciences in Israel, with roughly half of its medical research and a significant biotechnology industry. For this reason, Jerusalem Mayor, Mr. Nir Barkat, together with the City Council has marked as top priority the development of Jerusalem as the capital of the Israeli Bio-med Industry.

Program:
Moderator: Michael Horesh, JBNF

Greetings from

Mayor Nir Barkat

Deputy Mayor Naomi Tsur

Opening: Mr Avi Salman, Director, Business Development, Business Promotion Department

Ms. Chen Levin, Executive Director, BioJerusalem

Guest of Honor:

Launching Burrill Israel Fund - The Latest Jerusalem BioMed Fund

Jeffrey Miller,

Special Advisor to Burrill & Company and CEO of Miller Communications Group

Launching of the JBNF-BioMed Forum, the new JBNF section dedicated to business networking in Bio-Med in the Jerusalem area.

Welcome the JBNF-BioMed Forum new organizing committee:

Esther Moscatel-Mendelsohn, Kerentech,

Daniel Green, Yigal Arnon & Co., Law Firm

Joshua Hextor, BioLine Rx

Avigail Frij

About Jeffrey Miller:

Jeffrey Miller founded Miller Communications Group (MCG) in 2008, after building a successful career in the Life Science and Information Technology industries. MCG is a specialty consulting firm offering capital and investor relation services, business development, marketing and media services to early stage Life Science and Technology companies. From 2003 to 2008, Mr. Miller was Managing Director of Burrill & Company’s Life Sciences Media Group and on the Executive Committee.

http://photos1.meetupstatic.com/photos/event/1/8/9/e/event_116106302.jpeg

He launched and managed a number of media publications including The Journal of Life Sciences and The Biotech State of the Industry Report. He also launched and led such re-known and respected annual conferences as The Personalized Medicine Meeting, The CEO Biotech Meeting at Laguna Niguel, The India/China Life Sciences Meeting, and The Stem Cell Summit. These annual events enabled Burrill & Company to stay on the cutting edge of the life sciences industry, to maintain ties with the leading companies, CEOs and the most promising new technologies – making Burrill & Company the “best networked” company in the industry.

Prior to Burrill & Company, Miller spent nearly 20 years in Information Technology media, launching and managing publications, expositions and conferences. Most notable amongst these are The Internet Industry Standard and TheStandard.net, one of the fastest growing publications in the US in the ‘90s, Windows Magazine, PC Magazine, MacUser Magazine, Visual Basic Programmer’s Journal, Java Pro Magazine, Telecom Asia, Wireless Asia and America’s Network. Miller worked as a media executive with Nielsen Business Media, IDG Publications, CMP Publications, and Ziff-Davis Publishing. Early in his career he was an Account Executive with Ted Bates & Company and Savitt, Tobias & Balk Advertising Agencies in NY. Jeff has an MBA in Marketing Management.nched and managed a number of media publications including The Journal of Life Sciences and The Biotech State of the Industry Report. He also launched and led such re-known and respected annual conferences as The Personalized Medicine Meeting, The CEO Biotech Meeting at Laguna Niguel, The India/China Life Sciences Meeting, and The Stem Cell Summit. These annual events enabled Burrill & Company to stay on the cutting edge of the life sciences industry, to maintain ties with the leading companies, CEOs and the most promising new technologies – making Burrill & Company the “best networked” company in the industry.

More about the G. Steven Burrill and the Burill & Company:

G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 40 years. Mr. Burrill founded and has been Chief Executive Officer of Burrill & Company, a venture capital and merchant banking firm, since 1994. Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and coordinating the firm's services to clients in the field of biotechnology, life sciences, high technology, and manufacturing worldwide. He currently serves on the Boards of Directors of AliveCor (Chairman), Catalyst Biosciences, Depomed (NASDAQ: DEPO), NewBridge, Novadaq (TSX: NDQ), Targacept (NASDAQ: TRGT) and XDx. Previously he served as Chairman of the Boards of BioImagene, Abunda Nutrition and Pharmasset.

The Burrill & Company is a diversified global financial services firm focused on the life sciences industry. With $1.5 billion in assets under management, the firm's businesses include venture capital/private equity, merchant banking, and media. By leveraging the scientific and business networks of its team, Burrill & Company has established unrivaled access and visibility in the life sciences industry. Headquartered in San Francisco, the company oversees a global network of offices throughout the United States, Latin America, Europe, and Asia.